M&A Deal Summary

Cytiva Acquires Vanrx Pharmasystems

On February 1, 2021, Cytiva acquired machinery company Vanrx Pharmasystems

Acquisition Highlights
  • This is Cytiva’s 1st transaction in the Machinery sector.
  • This is Cytiva’s 1st transaction in Canada.
  • This is Cytiva’s 1st transaction in British Columbia.

M&A Deal Summary
Date 2021-02-01
Target Vanrx Pharmasystems
Sector Machinery
Buyer(s) Cytiva
Deal Type Add-on Acquisition

Target

Vanrx Pharmasystems

Burnaby, British Columbia, Canada
Vanrx Pharmasystems, Inc. is a Canadian company that makes robotic aseptic filling machines to fill vials, syringes, and cartridges with reduced risk and increased speed to patients. Vanrx Pharmasystems was founded in 2007 and is based in Burnaby, British Columbia.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Cytiva

Marlborough, Massachusetts, United States
Category Company
Sector Life Science
DESCRIPTION

Cytiva is a provider of technologies and services that advance and accelerate the development and manufacture of therapeutics. Cytiva brings speed, efficiency, and capacity to research and manufacturing workflows, enabling the development, manufacture, and delivery of transformative medicines to patients. Cytiva is based in Marlborough, Massachusetts.

DEAL STATS #
Overall 1 of 2
Sector (Machinery) 1 of 1
Type (Add-on Acquisition) 1 of 2
State (British Columbia) 1 of 1
Country (Canada) 1 of 1
Year (2021) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-10-06 Cevec

Köln, Germany

Cevec is a provider of high-performance cell technology for the manufacturing of advanced bio-therapeutics from R&D to manufacturing scale. The company’s product portfolio comprises platform technologies for gene therapy viral vectors, vaccines, and complex recombinant proteins. With the ELEVECTA Technology, Cevec offers a unique solution for large-scale production of AAV vectors using helper virus-free producer cell lines with all necessary components stably integrated into the cell. The technology is based on suspension cells and does not require any expensive transfection reagents nor cGMP plasmids. The company's CAP Ad Technology is the ideal production platform for RCA-free adenoviral vectors. Based on human suspension cells, it allows for a robust manufacturing process, easy scale-up from research grade to industrial volumes and thus opens the way for various applications, from gene therapy to vaccine production. With CAP-Go Technology, it provides a solution to the increasing need for recombinant production of complex and highly glycosylated protein molecules, including laminins, coagulation factors, and plasma proteins. Cevec was formed in 2003 and is based in Köln, Germany.

Buy -
Mergr

Product

Company

Legal